Despite the promise of ICIs therapy, less than 20% of patients with NSCLC respond to immunotherapy alone, and a large proportion do not respond to PD-1/PD-L1 monotherapy, while some patients suffer severe irAEs. The gene discussed is CD274; the disease is non-small cell lung carcinoma.